We are live on ! Find out more
QTTB icon

Q32 Bio

59 hedge funds and large institutions have $15.9M invested in Q32 Bio in 2023 Q2 according to their latest regulatory filings, with 7 funds opening new positions, 6 increasing their positions, 19 reducing their positions, and 10 closing their positions.

New
Increased
Maintained
Reduced
Closed

4,000% more call options, than puts

Call options by funds: $41K | Put options by funds: $1K

0.15% less ownership

Funds ownership: 1.87%1.72% (-0.15%)

5% less funds holding

Funds holding: 6259 (-3)

21% less capital invested

Capital invested by funds: $20M → $15.9M (-$4.13M)

30% less first-time investments, than exits

New positions opened: 7 | Existing positions closed: 10

68% less repeat investments, than reductions

Existing positions increased: 6 | Existing positions reduced: 19

Holders
59
Holders Change
-3
Holders Change %
-4.84%
% of All Funds
0.93%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
7
Increased
6
Reduced
19
Closed
10
Calls
$41K
Puts
$1K
Net Calls
+$40K
Net Calls Change
+$1K

QTTB Hedge Fund Activity: Q2 2023 in Review

59 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in Q32 Bio (QTTB) for Q2 2023, worth a combined $15.9M — down 21% from $20M a quarter earlier.

Sellers outnumbered buyers: 10 funds closed out of QTTB and 7 opened new positions — a net loss of 3 holders — while 19 trimmed existing stakes and 6 added.

The largest buyer was Assenagon Asset Management, adding an estimated $31.7K. The largest seller was JP Morgan Chase, cutting an estimated $411K.

  • 59 institutional investors held Q32 Bio (QTTB) as of Q2 2023, down from 62 in Q1 2023.
  • Funds reported $15.9M of Q32 Bio stock for Q2 2023, down 21% quarter-over-quarter.
  • 7 funds opened new Q32 Bio positions in Q2 2023 and 10 closed out, a net change of -3 holders.
  • The largest Q32 Bio buyer in Q2 2023 was Assenagon Asset Management, an estimated $31.7K added.
  • The largest Q32 Bio seller in Q2 2023 was JP Morgan Chase, an estimated $411K sold.

Based on aggregated 13F filings for Q2 2023.